tetano
Editor, Senior Moderator
Nat Immunol
. 2022 Aug 29.
doi: 10.1038/s41590-022-01292-1. Online ahead of print.
Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2
Mariana O Diniz[SUP] #[/SUP][SUP] 1 [/SUP], Elena Mitsi[SUP] #[/SUP][SUP] 2 [/SUP], Leo Swadling[SUP] 1 [/SUP], Jamie Rylance[SUP] 2 [/SUP], Marina Johnson[SUP] 3 [/SUP], David Goldblatt[SUP] 3 [/SUP], Daniela Ferreira[SUP] 4 5 [/SUP], Mala K Maini[SUP] 6 [/SUP]
Affiliations
Abstract
T cells can contribute to clearance of respiratory viruses that cause acute-resolving infections such as SARS-CoV-2, helping to provide long-lived protection against disease. Recent studies have suggested an additional role for T cells in resisting overt infection: pre-existing cross-reactive responses were preferentially enriched in healthcare workers who had abortive infections[SUP]1[/SUP], and in household contacts protected from infection[SUP]2[/SUP]. We hypothesize that such early viral control would require pre-existing cross-reactive memory T cells already resident at the site of infection; such airway-resident responses have been shown to be critical for mediating protection after intranasal vaccination in a murine model of SARS-CoV[SUP]3[/SUP]. Bronchoalveolar lavage samples from the lower respiratory tract of healthy donors obtained before the COVID-19 pandemic revealed airway-resident, SARS-CoV-2-cross-reactive T cells, which correlated with the strength of human seasonal coronavirus immunity. We therefore demonstrate the potential to harness functional airway-resident SARS-CoV-2-reactive T cells in next-generation mucosal vaccines.
. 2022 Aug 29.
doi: 10.1038/s41590-022-01292-1. Online ahead of print.
Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2
Mariana O Diniz[SUP] #[/SUP][SUP] 1 [/SUP], Elena Mitsi[SUP] #[/SUP][SUP] 2 [/SUP], Leo Swadling[SUP] 1 [/SUP], Jamie Rylance[SUP] 2 [/SUP], Marina Johnson[SUP] 3 [/SUP], David Goldblatt[SUP] 3 [/SUP], Daniela Ferreira[SUP] 4 5 [/SUP], Mala K Maini[SUP] 6 [/SUP]
Affiliations
- PMID: 36038709
- DOI: 10.1038/s41590-022-01292-1
Abstract
T cells can contribute to clearance of respiratory viruses that cause acute-resolving infections such as SARS-CoV-2, helping to provide long-lived protection against disease. Recent studies have suggested an additional role for T cells in resisting overt infection: pre-existing cross-reactive responses were preferentially enriched in healthcare workers who had abortive infections[SUP]1[/SUP], and in household contacts protected from infection[SUP]2[/SUP]. We hypothesize that such early viral control would require pre-existing cross-reactive memory T cells already resident at the site of infection; such airway-resident responses have been shown to be critical for mediating protection after intranasal vaccination in a murine model of SARS-CoV[SUP]3[/SUP]. Bronchoalveolar lavage samples from the lower respiratory tract of healthy donors obtained before the COVID-19 pandemic revealed airway-resident, SARS-CoV-2-cross-reactive T cells, which correlated with the strength of human seasonal coronavirus immunity. We therefore demonstrate the potential to harness functional airway-resident SARS-CoV-2-reactive T cells in next-generation mucosal vaccines.